A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients ≥ 18 years of age.
Ankylosing spondylitis as defined by the modified New York criteria for ≥ 3 months prior to baseline.
Active disease at screening and baseline (Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] ≥ 4.0, spinal pain visual analog scale \[VAS\] ≥ 40).
Inadequate response or intolerant to 1 or more previous non-steroidal anti-inflammatory drugs (NSAIDs).
Inadequate response to treatment with etanercept, infliximab, adalimumab, or golimumab because of inadequate efficacy.
Tumor necrosis factor (TNF) antagonist therapy must have been discontinued at least 8 weeks prior to baseline (etanercept 4 weeks).
Traditional disease-modifying anti-rheumatic drugs (DMARDs) must be withdrawn for at least 4 weeks prior to baseline (methotrexate, sulfasalazine, and hydroxychloroquine or chloroquine may be allowed if at stable dose for at least 4 weeks prior to baseline).
Oral corticosteroids (≥ 10 mg/day prednisone or equivalent) and NSAIDs/cyclooxygenase-2 \[COX-2\] inhibitors must be at stable dose for at least 4 weeks prior to baseline.
You may not be if
Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after randomization.
Total ankylosis of spine (as determined by investigator).
Inflammatory rheumatic disease other than ankylosing spondylitis.
Active, acute uveitis at baseline.
Previous treatment with tocilizumab.
Intra-articular or tendon injections or parenteral corticosteroids within 4 weeks prior to screening.
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
Active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infection.
History of or currently active primary or secondary immunodeficiency.
Body weight \> 150 kg.
Clareo Health | A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
